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Expanding medical knowledge increases the potential risk of medical errors in clinical practice. We present, OPAD, a clinical
decision support system in the field of themedical care of osteoporosis.We utilize clinical information from international guidelines
and experts in the field of osteoporosis. Physicians are provided with user interface to insert standard patient data, from which
OPAD provides instant diagnostic comments, 10-year risk of fragility fracture, treatment options for the given case, and when to
offer a follow-up DXA-evaluation. Thus, the medical decision making is standardized according to the best expert knowledge at
any given time. OPAD was evaluated in a set of 308 randomly selected individuals. OPAD’s ten-year fracture risk computation is
nearly identical to FRAX (r = 0.988). In 58% of cases OPAD recommended DXA evaluation at the present time. Following a DXA
measurement in all individuals, 71% of those that were recommended to have DXA at the present time received recommendation
for further investigation or specific treatment by the OPAD. In only 5.9% of individuals in which DXA was not recommended, the
result of the BMDmeasurement changed the recommendations given by OPAD.
1. Introduction
According to the International Osteoporosis Foundation
(IOF), one in three women and one in five men will experi-
ence an osteoporotic fracture later in their life; thus, globally
an osteoporotic fracture is estimated to occur every third
second [1–3]. In that context, nine million North Americans
have osteoporosis and it is estimated that 43 million have low
bone mass measured by DXA (http://nof.org/news/1648), a
precursor of osteoporosis, known as osteopenia.TheNational
Osteoporosis Foundation (NOF) in the USA has estimated
that, in USA alone, osteoporosis related fractures number
two million every year resulting in an annual cost of $19
billion [4]. Due to the increasing numbers of elderly people,
the number of fractures will increase to three million in 2025,
resulting in a $25.3 billion annual cost in the USA [5].
Correctly prescribed bone protective treatment may reduce
the fracture risk by 30–50% in only three years [6]. It is
therefore critical to identify individuals at risk of a fragility
fracture and offer them the treatment protocols to decrease
the number of fractures in coming years.
The diagnosis of osteoporosis has traditionally relied on
bone mineral density (BMD) measurement [7–9]. However,
a number of other factors affect a physicians’ decision to treat
osteoporosis, including family history, lifestyle, and various
medical factors [10]. The incorporation of all of these factors
into a treatment recommendation and a decision to perform a
BMD scan can be a formidable task that requires considerable
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expert knowledge and experience. Here we describe the deve-
lopment of a clinical decision support system that automates
the dissemination of this knowledge.
Currently available risk calculator systems for osteoporo-
sis, for example, FRAX [11], Garvan [12], and Qfracture [13],
provide the user with ten-year probability of fragility fracture
related to osteoporosis. While this informationmay be useful
for a number of users, fracture risk is known to be difficult for
the layperson to interpret [14] and even for nonexpert health
professionals. Furthermore, it is not immediately evident
how this information is to be interpreted, for example, for
treatment decision in daily clinical practice. Clinical decision
support systems (CDSS) have been suggested as a means of
disseminating knowledge of best practice to physicians [15],
electronic medical reminders have been shown to improve
osteoporosis management after fractures [16], and Kastner
and Straus [17] have concluded that “multi-component tools
that are targeted to physicians and patients may be effective
for supporting clinical decision making in osteoporosis dis-
ease management.”
We have developed a clinical decision support system
that gives the 10-year fracture probability due to osteoporosis
for the individual patient, lifestyle recommendations, and
recommendations as to whether and when a BMD scan is
recommended. Furthermore, the systemwill identify patients
at risk of fractures and would benefit from specific preventive
medical treatment. Our osteoporosis adviser (OPAD) is
designed for those with medical knowledge such as general
physicians and clinical nurse specialists.
In this paper, we evaluate the reliability of the OPAD
system by comparing its 10-year fracture probability with the
probability given by FRAX and by assessing the quality of its
BMD scanning recommendations, that is, whether those that
were recommended to have a BMD measurement benefited
from the measurement.
2. Materials and Methods
2.1. The Osteoporosis Advisor (OPAD). We have designed an
expert system to assist in the diagnosis and treatment of
osteoporosis. The software takes as input a set of clinically
relevant parameters from which the 10-year fracture risk is
computed based on published country specific data [8, 11, 18].
The output of the program is as follows: the 10-year fracture
risk of an individual, lifestyle and treatment recommenda-
tions, and lastly a suggestion for the time when a follow-up
BMD scan should take place. The clinically relevant param-
eters and the computed risk for fracture are used as input
into an expert system which gives specific recommendations
for each case with respect to lifestyle changes and treatment
options.
The software further outputs immediately relevant infor-
mation to the user: a risk group for the individual (low, med-
ium, or high risk for fracture compared to age-matched con-
trols [18, 19]) and a diagnosis of osteopenia, osteoporosis, or
manifested osteoporosis (osteoporosis with fracture), as well
as for glucocorticosteroid induced osteoporosis. Diagnosis of
osteoporosis is made according to theWHO definitions [20],
Table 1: Patient attributes used by the osteoporosis advisor.
Age
Bone mineral density (𝑇 value)
Ethnicity
Gender
Previous osteoporotic related fracture
Parent hip fracture
Current smoking
Current use of glucocorticosteroids for more than three months
Rheumatoid arthritis
Secondary osteoporosis
Alcohol: 3 or more units per day
Hormone replacement therapy
Regular exercise
Sufficient calcium intake
Sufficient vitamin D intake
where osteoporosis is diagnosed when BMD results in a 𝑇
value of −2.5 or lower; that is, the BMD is ≥2.5 SD below the
mean of young individuals of the same sex and reach, and
osteopenia is diagnosed when the 𝑇 value is between −1 and
−2.5.
2.2. Design of Expert System. The design of the system uses
a knowledge mapping approach. Expert physicians were
queried to determine the clinically relevant parameters for
the recommendation of osteoporosis treatment and rec-
ommendations for BMD measurements. A group of dif-
ferent specialists who were all interested in osteoporosis
(rheumatologist, endocrinologist, general practitioner, and
geriatrician) participated in the process. The Intellix Advisor
[21, 22] was used for knowledge capture in the model.
The Intellix Advisor allows for active acquisition of
knowledge. A set of instances is input into the software and
from these input examples the software can be told either
to construct a neural network based model based on the
examples or to ask for more examples that consist of patients
not considered by the model. In our approach patients were
added to the model until a diagnosis or recommendations
could be made for every possible tested patient. The model
is implemented as a lookup table and for every new patient
diagnosed a patient with the same characteristics is found in
our database.
The diagnosis for a patient includes four distinct pieces of
information: 10-year fracture risk, lifestyle recommendations,
treatment recommendations, and recommendation of the
time for the next BMDmeasurement or follow-up evaluation
of the individual patient. Initially a set of clinically relevant
parameters was determined (see Table 1).
2.3. Knowledge Capture of Treatment Recommendations. The
OPAD system follows the frame of international guidelines,
for example, the Scottish Intercollegiate Guidelines Network
(SIGN) on osteoporosis (http://sign.ac.uk/pdf/sign71.pdf),
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Table 2: Patient attributes used for the recommendation of osteo-
porosis treatment.
Attribute Type
Gender Male/female
GIOP Yes/no
Fragility fracture Yes/no
Fracture risk High/medium/low
Treatment Yes/no
Secondary osteoporosis Yes/no
𝑇 value Numerical
Age Numerical
Menopause status Before/<3 years/>3 years
Diagnosis None/osteopenia/osteoporosis/manifestosteoporosis/GIOP
and the system also takes into account regional differences,
that is, local or national guidelines. However, the system pre-
dominantly relies on knowledge capture process of the expert
panels, as guidelines never cover all cases. In the end a total
of fifteen different treatment recommendations were initially
identified as possible recommended treatment options for
osteoporosis. The recommended treatments ranged from no
treatment to specific recommendations for which drug class
was the most appropriate, either as a preventive measure or
as a treatment for manifest osteoporosis.
Table 2 lists the clinically relevant patient attributes
determined by our expert physicians. Different medical
specialists with expertise in osteoporosis reviewed a list of
cases that had recently visited the osteoporosis clinic at the
University Hospital in Reykjavik (LSH), Iceland. For each
patient the physicians reviewed their clinical decision and
were then asked to determine which of the clinically relevant
parameters influenced his decision. The clinically relevant
information and the diagnoses were entered into the Intellix
Advisor, leaving those clinical relevant parameters that were
not relevant for the decision as “do not care.” After consid-
ering the set of real patient cases and their detailed experts’
reviews, the Intellix Advisor software constructed a set of
virtual patients having clinical characteristics not observed
among the list of cases already considered. This process was
continued until the space of all possible patients was covered;
a decision could be reached for all possible patients that could
enter the clinic, independent of clinical characteristics. As a
result a total of 80 relevant rules were constructed in the final
outcome of the system.
2.4. Time until Next DXA Measurement. The recommended
time until the next DXA measurement was also determined
by using a knowledge mapping process. A list of clinically
relevant pieces of information was determined which can be
seen in Table 3.
Seven different recommendations were made for the
time for the next BMD measurement, listed in Table 4. The
construction of the clinical decision model then followed
Table 3: Attributes used to determine time until next DXA mea-
surement.
Attribute Type
Gender Male/female
Menopause Before, <3 years, >3 years
Risk group High/medium/low
Treatment Yes/no
Changes in BMDmeasured by
DXA
No DXA/improving/unknown
or losing/fast loosing/neutral
Glucocorticosteroids Yes/no
Table 4:Thepossible recommendations for the next time for a BMD
scan.
At menopause
At the age of 65
Now
In 1-2 years
In 3 years
In 5 years
DXA not recommended
the same protocol as described above for the treatment rec-
ommendations. In the end a total of 87 rules were determined
to be clinically relevant.
2.5. Capture of Disease Risk Models. The computed 10-year
risk of fracture was based on the World Health Organization
(WHO) fracture risk assessment recommendations [19, 20].
Thus, the fracture risk predications delivered by our system
are comparable to the results given by FRAX [18]. The output
of the FRAX in collaboration with NOGG recommendation
guidelines also includes the classification of individuals into
high, medium, and low risk individuals [23]. The FRAX
recommendation guidelines are given as a set of text tables,
with the risk of fracture and confidence interval for the risk
of fracture given as a function of age and the number of risk
components an individual has. As the tables only give fracture
risk probabilities for selected age groups, an interpolation is
done to compute the fracture risk probabilities for other age
groups.
2.6. Model Testing. In order to validate that the treatment
recommendations presented to the end user agreed with the
treatment recommendations originally determined for each
patient a quality control module was developed. Thus, built
on top of our clinical database a set of 300 virtual quality
control patients was createdwhichwere used to automatically
verify the correctness of the system recommendations for
real life clinical information given for each case. Experiments
verified that the results of these patients agreed in both the
model created and the interface to the end user.
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2.7. Test in Real Life. As the WHO recommendation guide-
lines are not given with a closed form formula we compared
the fracture risk computation given by our OPAD system
with the fracture risk computation given by FRAX. We
selected consecutive 308 individuals from the out-patient
osteoporosis clinic at LSH, who visited the clinic from the 1st
of January 2012 onwards. We compared the ten-year fracture
risk computed using the OPAD and the ten-year fracture risk
computed using recommendations given by our model with
those given by FRAX. Linear regression was run to compare
the results between the two systems.
We also reevaluated the same group of 308 individuals
with our OPAD system with respect to the need of DXA at
the present time or later; that is, the risk evaluation was done
without theDXA results (𝑇 value).We then analyzedwhether
the DXA result, that is, in those cases where OPAD did not
recommendDXA at the given time, influenced the automatic
treatment and the follow-up recommendations given by the
OPAD compared to the recommendations by the experts,
who had access to all the clinical data.
2.8. Ethics Statement. TheData Protection Authority (S5680)
and the National Bioethics Committee of Iceland approved
the study protocol (VSNb2010050008). The original patients’
data were hosted by the University Hospital, Reykjavik,
Iceland. The data were anonymized before being provided to
the researchers.
3. Results
3.1. Correlation between Risk Evaluation by OPAD and FRAX.
Of the 308 cases, 39 were males and 269 were females, with a
mean age of 61 years (15–89). Figure 1 shows the 10-year frac-
ture riskwhenDXA is included presented by the two different
programs, that is, OPAD and FRAX. We obtained a correla-
tion of 𝑟 = 0.988 with a mean paired difference of 0.7678%
(SD = 1.9946%) when comparing individual patient prior to
DXA evaluation and 𝑟 = 0.977, mean difference 1.8285%
(SD = 2.8%) when DXA result were included in the risk
evaluation or a near perfect correlation between these two
risk calculators.
3.2. OPAD and Next DXA. These 308 patients were reevalu-
ated by the OPAD with respect to the need for a DXA at the
present time or later, that is, before they underwent theirDXA
evaluation.
In 178 cases (58%), out of these 308 cases, the OPAD
system recommended DXA evaluation at the present time.
Following DXA measurement in these 178 cases, 91 (51%) of
those received OPAD recommendation on specific treat-
ment options, where 5 patients (3%) were recommended to
continue with their treatment. Additional 31 patients (17%)
received recommendation on consulting specialist in osteo-
porosis. Meanwhile, only 51 of these 178 cases (29%) received
general prevention measurement recommendations. Thus,
the DXA investigation performed according to the recom-
mendation of the OPAD system seems to influence the
clinical decision-making process.
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Figure 1: Ten-year risk for major osteoporotic fracture computed
using the osteoporosis advisor (OPAD; 𝑥-axis), compared to the
fracture risk computed using FRAX (𝑦-axis).
Out of the 308 original cases, 102 cases (33%) came for
their DXA even though the OPAD system would have
recommended that they should have their DXA at the age
of 65; that is, every third patient who came in for a measure-
ment did not need the DXA evaluation at the present time
according to the OPAD system.
3.3. Influence of DXA on OPAD Recommendations. In only
six of these 102 cases (5.9%), did the OPAD system change its
recommendation following the BMD measurement? In four
cases the OPAD recommended specific bone protective
treatment, due to the fact that these four individuals were
diagnosed with osteoporosis with a significantly increased
risk of fragility fracture, that is, with a 10-year fracture risk
in the range from 9.1% to 14.3%. In two additional cases
the OPAD changed its recommendation to continuation of
already taken measurements.
In a further 22 cases of these 308 cases (7.1%) the OPAD
system recommended DXA within 1–3 years depending on
various clinical circumstances. Independent of these recom-
mendations all patients received a DXA measurement, like
other patients in this study and only one of these individuals
received a different recommendation following the DXA
evaluation.
4. Discussion
Osteoporosis is a disorder affecting the density and infras-
tructure of the bone mass [20]. In its worst outcome it can
lead to the so-called fragility fractures [24], most frequently
seen in the vertebral spine, wrist, and the hip. Due to
their critical location, such fractures most often result in a
debilitating outcome for those affected individuals leading to
a significantly negative impact on not only their quality of life
but also individual life expectancy [25]. Despite an effective
drug treatment being readily available for affected patients, it
has been recognized that the majority of individuals at risk
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Figure 2: A 62-year-old Swedish female patient with history of fracture whose mother also had a history of hip fracture. She did not have
other medical risk factors and she had osteopenia according to a recent DXA evaluation with a 𝑇-score of −2.0.
and also those already affected with osteoporosis and increa-
sed risk of fragility fracture are not correctly diagnosed
or go unnoticed and therefore miss potentially lifesaving
therapeutic measures [6]. Thus, even patients who have
suffered fragility fractures and have been exposed to the
healthcare system are not identified and treated with the
proper preventive regimen they deserve. In this context, if
correctly implemented clinical decision support systems such
as the one presented here (OPAD) should have the potential
to improve both public and healthcare workers awareness
of osteoporosis [15]. Such measures not only would improve
and streamline the diagnosis process but would also become
a valid diagnosis aid to secure the optimal treatment and
outcome of our osteoporotic patients.
Bone mineral density (BMD), that is, bone mass, may
be measured with several methods, for example, quantitative
ultrasound (QUS), peripheral quantitative computer tomog-
raphy (pQCT), and dual energyX-ray absorptiometry (DXA)
which is the golden standard of bone mass measurement.
Most professional interest groups, for example, NOF and
IOF, have published recommendations on when to use DXA
for BMD measurement [26], while others research groups
supported by the National Institutes of Health have made an
effort to analyze the need of rescreening in postmenopausal
women [27]. As osteoporosis is a silent disease until the
fracture occurs, BMD measurement is the only method to
diagnose osteoporosis prior to the fracture. However, the
access to DXA-machines is limited in most countries, and it
is therefore important to find those at risk of osteoporosis
for DXA-evaluation and those individuals who receive the
greatest benefits from the investigation. Thus, improving the
cost efficiency by correctly identifying those at risk and those
who should be referred for BMD should lead to shorter
waiting lists for specialist referrals and improved diagnostic
accuracy. Our finding that more than one third of BMD
tested patients could be identified a priori to be at no risk of
osteoporosis related fractures, thus, did not benefits from the
DXA evaluation.
Several risk calculator tools for bone fractures have
been presented, but only FRAX has been recommended and
supported by theWorld Health Organization (WHO). FRAX
was developed for the calculation of the 10-year fracture risk
for hip fracture or a major osteoporotic fracture (clinical
spine, forearm, hip, or shoulder fracture) based on certain
risk factors, with or without results of DXA measurement of
the hip. FRAX offers country specific values for several coun-
tries in Europe, North and Latin America, the Middle East,
Africa, and Oceania, or a total of 52 country specific datasets
[18]. However, FRAX does not give any specific diagnosis
or treatment options, and neither have they reported their
algorithms used to derive the 10-year fracture risk. Further
analysis of our 10-year fracture risk in context to the given
recommendation by our OPAD is in progress, before we can
make our methodology public in detail.
The busy clinician may have difficulties in interpreting
the risk value figure for each patient in hectic daily clinical
practice.With this inmindwe have extended the information
provided by OPAD, by giving a specific diagnosis, that is,
osteoporosis or osteopenia, and specific recommendations
on prevention, time of next DXA, and treatment options
according to international guidelines and experts knowledge
[10]. In addition, our results are presented on an interactive
riskometer, which gives a comparison to the background
population of the same sex and age, both graphically and by
calculation of the 𝑍 value for the individual patient (please
see Figure 2).
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Although physicians subscribe to several medical jour-
nals, presenting thousands of articles yearly, they have diffi-
culty in keeping up to date in all areas in their daily practice.
The more complicated medical world amplifies the risk of
diagnosis errors. OPAD allows “best practice” in osteoporosis
risk evaluation of fragility fractures and treatment to be
captured, distributed, and automated in a simple bedside
manner for the busy practicing physician and other health
care providers, including nurses working in fracture liaison
services, as now highly recommended by IOF [28]. Although
the OPAD system presented in this present study reflects
Swedish data, it runs in ten different national specific datasets.
Improvements in treatment alternatives or changes in clinical
guidelines can easily be incorporated into the OPAD system;
even country specific guidelines can be internalized. Further
studies are needed to analyze whether a clinical approach
with the help of digital CDSS tools, such as OPAD, may not
only improve individual care, but also become highly cost
effective. Such studies need to involve primary care, fracture
clinics, and in-hospital fracture liaison services. Furthermore,
survey among primary care doctors regarding their use of and
evaluation of theOPAD system, including their assessment of
how to implement clinical discussion system, such as OPAD,
was carried on fracture risk management and treatment in
daily clinical primary care praxis.
We conclude that OPAD is accurate in respect to fracture
risk probability evaluation and may presumptively be cost
effective in fracture liaison services. However, cost-benefit
studies are needed in the field of osteoporosis preventive care
and CDSS.
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